​Vertex raises price of top-selling cystic fibrosis drug for first time

Vertex Pharmaceuticals has raised the price of its best-selling cystic fibrosis drug for the first time, in a move that could boost revenues at the Boston-based company. The decision by Vertex (Nasdaq: VRTX) to increase the list price of Orkambi by 5 percent, to around $273,000 per year before discounts, was first reported by Cowen analyst Phil Nadeau in a note on Wednesday morning and later confirmed by a spokeswoman for the company. Vertex had not previously ra ised the price of Orkambi, which…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news